Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Freeline Therapeutics Holdings plc Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Investor presentation by the Company",
"Investor presentation by the Company"
10/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET"
08/15/2023 6-K Quarterly results
Docs: "Freeline Reports Second Quarter 2023 Financial Results and Business Highlights Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson’s disease Management to host conference call at 8:00 a.m. ET today"
07/17/2023 SC 13G INTEGRATED CORE STRATEGIES LLC reports a 8.5% stake in FREELINE THERAPEUTICS HOLDINGS PLC
05/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Notice of Annual General Meeting",
"Form of Proxy for Holders of Ordinary Shares",
"Freeline Therapeutics Holdings plc Annual Report and Accounts for the fiscal year ended December 31, 2022",
"Depositary's Notice of Annual General Meeting",
"2023 Voting Instructions for Holders of American Depositary Shares"
05/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Completes ADS Ratio Change"
04/21/2023 F-6 POS Form F-6 POS - Post-effective amendments for immediately effective filing:
04/21/2023 6-K Quarterly results
04/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring organization and pausing development of FLT190 to extend cash runway into Q2 2024 Appointed CFO Paul Schneider to Board of Directors Management to host conference call today at 8 a.m. ET"
04/04/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/14/2023 SC 13G/A EVENTIDE ASSET MANAGEMENT, LLC reports a 9.1% stake in Freeline Therapeutics Holdings plc
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 6-K Quarterly results
01/31/2023 SC 13G/A Tetragon Financial Management LP reports a 6.2% stake in Freeline Therapeutics Holdings plc
11/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Receives Approval to Transfer to Nasdaq Capital Market"
11/15/2022 6-K Quarterly results
Docs: "6-K",
"Freeline Reports Third Quarter 2022 Financial Results and Corporate Update Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies Streamlining organization and extending cash runway into 2024 Prioritizing development of FLT201 in Gaucher disease and FLT190 in Fabry disease; ceasing investment in further development of FLT180a in hemophilia B Updated data from first cohort of MARVEL-1 trial show FLT190 continues to be well-tolerated with sustained a-Gal A enzyme increases up to three years after dosing"
10/04/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease"
08/26/2022 6-K Quarterly results
08/09/2022 6-K Quarterly results
07/11/2022 6-K Quarterly results
06/30/2022 F-6EF Form F-6EF - Registration of American Depository Receipt shares, immediately effective:
06/30/2022 6-K Quarterly results
06/15/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/14/2022 6-K Quarterly results
06/03/2022 6-K Quarterly results
05/23/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
04/19/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Freeline Appoints Paul Schneider as Chief Financial Officer"
04/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Reports Full Year 2021 Financial Results and Business Highlights Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease Extended financial runway and streamlined organization support Company"
03/31/2022 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/25/2022 SC 13D Syncona Portfolio Ltd reports a 62.3% stake in Freeline Therapeutics Holdings plc
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease Company to progress to second dose cohort in the MARVEL-1study immediately, with first patient dosing expected in mid-2022"
03/23/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy